Compare Quanta Services Inc (PWR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs ResMed Inc. — how do they compare? Quanta Services Inc trades at $705.94 (market cap $103.03B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: Quanta Services Inc is far larger — about 3.2× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Quanta Services Inc for 62 Days and ResMed Inc. for 51 Days on average.
| PWR | RMD | |
|---|---|---|
Market Cap | $103.03B | $31.89B |
Volume | 977,892 | 618,314 |
Sector | Industrials | Health |
52-Week High | $785.24 | $275.96 |
52-Week Low | $412.21 | $182.82 |
Typical Hold Time | 62 Days | 51 Days |
Enterprise Value | $109.13B | $31.24B |
Dividend Yield | 0.06% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PWR trades at $685.33, down 2.25% today but maintains strong technical momentum with bullish moving averages and support at $684. The company demonstrates robust fundamentals with revenue growth from $23.7B to $28.5B in 2025 and consistent earnings beats, while analyst sentiment remains overwhelmingly positive with 27 buy ratings and a $802.08 consensus target.
PWR offers compelling growth exposure to infrastructure and AI-driven data center demand, supported by a record $53B backlog and margin expansion potential. Key risks include execution challenges on large projects and sensitivity to economic cycles, but strong institutional support and positive earnings momentum suggest continued upside potential.
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
